Paul Andrew Moore's most recent trade in Zymeworks BC Inc was a trade of 70,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 66,000 | 66,000 | - | - | Performance Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 47,000 | 47,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 58,057 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 35,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.67 per share. | 12 Jan 2026 | 9,560 | 48,497 (0%) | 0% | 22.7 | 216,759 | Common Stock |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 51,212 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 20,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 17,168 | 40,501 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 17,168 | 0 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 10,821 | 40,391 (0%) | 0% | 25.1 | 271,574 | Common Stock |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 9,289 | 31,212 (0%) | 0% | 25.1 | 233,125 | Common Stock |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 79,000 | 79,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 53,000 | 53,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 34,741 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 40,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 17,166 | 24,533 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 17,166 | 17,168 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 11,408 | 23,333 (0%) | 0% | 14.9 | 170,254 | Common Stock |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 9,792 | 14,741 (0%) | 0% | 14.9 | 146,137 | Common Stock |
| Zymeworks BC Inc | Moore Andrew Paul | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Moore Paul Andrew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Andrew Moore Paul | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,166 | 17,166 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,166 | 34,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Andrew Paul Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 7,460 | 9,706 (0%) | 0% | 10.7 | 79,465 | Common Stock |
| Zymeworks BC Inc | Moore Paul Andrew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 2,339 | 7,367 (0%) | 0% | 11.2 | 26,233 | Common Stock |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 77,500 | 77,500 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 51,500 | 51,500 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) |